Effect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans

Authors:

Abstract
Background: Platelet activation is central to the pathogenesis of acute coronary syndromes. Surface expression ofP‐selectin on activated platelets induces formation of platelet–monocyte aggregates and promotes vascular inflammation and thrombosis.P‐selectin antagonism may represent a novel therapeutic strategy in vascular disease. We aimed to investigate the effects of the novelP‐selectin antagonistPSI‐697 on platelet–monocyte aggregate formation in humans.Methods and Results: In a double‐blind, randomized, placebo‐controlled crossover study, healthy smokers were randomized to receive either oralPSI‐697 600 mg or matched placebo. The sequence of treatment was also randomized, with all subjects receiving bothPSI‐697 and placebo. Platelet–monocyte aggregates were measured by flow cytometry at 4 and 24 hours in the presence and absence of thrombin receptor‐activating peptide (TRAP; 0.1 to 1.0 μm/L). Theex vivoaddition ofTRAPcaused a concentration‐dependent increase in platelet–monocyte aggregates from 8.2% to 94.8% (PPP>0.05).P‐selectin‐blocking antibody (CLB‐Thromb6), but notPSI‐697, inhibited both stimulated and unstimulated platelet–monocyte aggregate formation in vitro (P<0.001).Conclusions: The novel small‐moleculeP‐selectin antagonistPSI‐697 did not inhibit basal or stimulated platelet–monocyte aggregate formation in humans at the dose tested. Its clinical efficacy remains to be established.Clinical Trial Registration: URL:http://EudraCT.ema.europa.euUnique identifier: 2007‐005695‐14.

This publication has 31 references indexed in Scilit: